Bioarray Interview with CEOCFO magazine It was our pleasure to share some thoughts on being a diagnostic startup and what we think the future holds for Bioarray. "At Bioarray, we want to eliminate the error and fear inherent in cancer treatment by combining gene profiling with machine learning algorithms to identify [...]
About chrismoorecm1gmailcomThis author has not yet filled in any details.
So far chrismoorecm1gmailcom has created 27 blog entries.
Bioarray Genetics Named "Murphy's Innovator of the Month" WASHINGTON – U.S. Senator Chris Murphy (D-Conn.) announced on Tuesday that Bioarray Genetics, a Farmington biotech company housed at University of Connecticut’s (UConn) Technology Incubation Program (TIP), is “Murphy’s Innovator of the Month.” Bioarray Genetics focuses on using genomics and machine learning to predict the treatment [...]
2018 CT Entrepreneur of the Year: Scalable Venture April 20th, 2018 New Haven, CT It was with great honor tonight that Bioarray Genetics' CEO Founder, Marcia Fournier, won the 2018 CT Entrepreneur of the Year Award in the Scalable Ventures category. Nominations began in January 2018 and were judged by [...]
AACR Abstract: Isolation and detection of breast cancer cells in blood samples using antibody cocktails selected by large-scale genome-wide screeningchrismoorecm1gmailcom2018-04-20T05:05:25+00:00
Isolation and detection of breast cancer cells in blood samples using antibody cocktails selected by large-scale genome-wide screening Screening and prevention is critical to reducing breast cancer deaths, and mammography is not an ideal tool. To address this critical unmet need, we developed a panel of cell surface markers whose expression [...]
AACR Abstract: Genes involved in non-malignant breast phenotypes are widely expressed in multiple cancers and provide novel biomarkers of clinical outcomes and therapeutic responsechrismoorecm1gmailcom2018-04-20T05:06:20+00:00
Genes involved in non-malignant breast phenotypes are widely expressed in multiple cancers and provide novel biomarkers of clinical outcomes and therapeutic response We selected novel biomarkers based on non-malignant breast epithelial cell phenotypes and identified 325 genes (BA325) showing 32 significant oncology drug associations. A total of 251 genes out [...]
Bioarray Genetics awarded patent for breast cancer treatment predictive test Farmington-based molecular diagnostics company Bioarray Genetics Inc. has received a U.S. patent supporting its lead breast cancer predictive test. The patent covers methods and kits for predicting the effectiveness of breast cancer treatments. The method also generates a report indicating [...]
Bioarray Genetics Presents at the 40th Annual San Antonio Breast Cancer Symposium Bioarray Genetics announced today that the Company will be presenting a pivotal study at the upcoming 40th Annual San Antonio Breast Cancer Symposium on December 7th. Bioarray conducted a 582-patient clinical validation study that confirms the company's lead [...]
Bioarray Genetics Receives $4M in Series B Equity Financing Bioarray Genetics, a personalized medicine startup, announced today that it has received $4 million in Series B Equity Financing from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations. Bioarray, a personalized medicine [...]
AACR Abstract: A novel panel of 325 biomarkers is part of a large interconnected network representing multiple cell signaling pathways and allowing development of predictive tests for oncology drugschrismoorecm1gmailcom2018-04-20T05:30:58+00:00
A novel panel of 325 biomarkers is part of a large interconnected network representing multiple cell signaling pathways and allowing development of predictive tests for oncology drugs We developed an algorithm based on the gene expression of tumor biopsies to identify the best combination of biomarkers to reliably predict a [...]
AACR Abstract: Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarraychrismoorecm1gmailcom2018-04-25T03:51:08+00:00
Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarray With new developments of oncology drug combinations and targeted treatments, the ability to stratify categories of patient populations and to develop companion diagnostics has become increasingly important. A panel of 325 [...]